The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1443-1448

  Xie, Fa Jun ^a,b   Zhao, Peng ^c   Kou, Jun Yan ^a   Hong, Wei ^a   Fu, Li ^d   Hu, Lin ^a   Hong, Dan ^a   Su, Dan ^b   Gao, Yun ^b   Zhang, Yi Ping ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced NSCLC; Chemotherapy; GNAS1; Polymorphism; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSINE; GEMCITABINE; PLATINUM COMPLEX; THYMINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA DETERMINATION; DNA POLYMORPHISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GNAS1 GENE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84863808615     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1849-3     Document Type: Article

References (18)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
3. Lehnerdt GF, Franz P, WinterhoV S, Bankfalvi A, Grehl S, Lang S, Schmid KW, Siffert W, Jahnke K, Frey UH (2008) The GNAS1 T393C polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx. Laryngoscope 118:2172-2176
4. Frey UH, Fritz A, Rotterdam S, Schmid KW, PotthoV A, Altmeyer P, Siffert W, Brockmeyer NH (2010) GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. Eur J Med Res 15:422-427
5. Lehnerdt GF, Franz P, Zaqoul A, Schmitz KJ, Grehl S, Lang S, Schmid KW, Siffert W, Jahnke K, Frey UH (2008) Overall and relapsefree survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 14:1753-1758
6. Kaderi MA, Murray F, Jansson M, Merup M, Karlsson K, Roos G, Aleskog A, Tobin G (2008) The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. Leuk Res 32:984-987
7. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, Siffert W, Schmid KW (2007) The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 105:311-317
8. Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW, Siffert W (2005) The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14:871-877
9. Azzoli CG, Baker S Jr, Temin S, Pao W, AliV T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, PWster DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall- cell lung cancer. J Clin Oncol 27:6251-6266
10. Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Muller TH, Wurl P, Bond GL (2010) Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 70:172-180
11. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W (2009) TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64:355-360
12. Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, Kim YH, Mio T, Mishima M, Katakami N (2010) Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet 11:167
13. Knoefel LF, Werle-Schneider G, Dally H, Muller PJ, Edler L, Bartsch H, Tuengerthal S, Heussel CP, Reinmuth N, Thomas M, Risch A (2011) Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer. J Thorac Oncol 6:183-189
14. Frey UH, Lummen G, Jager T, Jockel KH, Schmid KW, Rubben H, Muller N, Siffert W, Eisenhardt A (2006) The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 12:759-763
15. Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, Jockel KH, Siffert W, Schmid KW (2005) GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 11:5071-5077
16. Alakus H, Monig SP, Warnecke-Eberz U, Alakus G, Winde G, Drebber U, Schmitz KJ, Schmid KW, Riemann K, Siffert W, Bollschweiler E, Holscher AH, Metzger R (2009) Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer. World J Gastroenterol 15:6061-6067
17. Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW, Baba HA (2007) GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 9:159-165
18. He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y (2010) Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. BMC Cancer 10:681